1. Home
  2. SFST vs OMER Comparison

SFST vs OMER Comparison

Compare SFST & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SFST
  • OMER
  • Stock Information
  • Founded
  • SFST 1999
  • OMER 1994
  • Country
  • SFST United States
  • OMER United States
  • Employees
  • SFST N/A
  • OMER N/A
  • Industry
  • SFST Major Banks
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • SFST Finance
  • OMER Health Care
  • Exchange
  • SFST Nasdaq
  • OMER Nasdaq
  • Market Cap
  • SFST 335.4M
  • OMER 304.9M
  • IPO Year
  • SFST 1999
  • OMER 2009
  • Fundamental
  • Price
  • SFST $45.21
  • OMER $4.15
  • Analyst Decision
  • SFST Buy
  • OMER Strong Buy
  • Analyst Count
  • SFST 1
  • OMER 5
  • Target Price
  • SFST $51.00
  • OMER $18.00
  • AVG Volume (30 Days)
  • SFST 18.9K
  • OMER 954.9K
  • Earning Date
  • SFST 10-21-2025
  • OMER 08-14-2025
  • Dividend Yield
  • SFST N/A
  • OMER N/A
  • EPS Growth
  • SFST 58.48
  • OMER N/A
  • EPS
  • SFST 2.69
  • OMER N/A
  • Revenue
  • SFST $102,878,000.00
  • OMER N/A
  • Revenue This Year
  • SFST $8.65
  • OMER N/A
  • Revenue Next Year
  • SFST $13.43
  • OMER $9,040.39
  • P/E Ratio
  • SFST $16.53
  • OMER N/A
  • Revenue Growth
  • SFST 15.60
  • OMER N/A
  • 52 Week Low
  • SFST $29.14
  • OMER $2.95
  • 52 Week High
  • SFST $46.00
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • SFST 60.20
  • OMER 49.06
  • Support Level
  • SFST $44.13
  • OMER $4.07
  • Resistance Level
  • SFST $45.36
  • OMER $4.34
  • Average True Range (ATR)
  • SFST 0.85
  • OMER 0.18
  • MACD
  • SFST -0.07
  • OMER -0.03
  • Stochastic Oscillator
  • SFST 64.14
  • OMER 11.76

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: